Melatonin
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Most useful when sleep timing is the problem: delayed sleep phase, jet lag, shift work, or age-related low nighttime signal.
Low-dose evening use is usually forgiving. The main hard edges are timing and context: do not eat after dosing, avoid strong CYP1A2 inhibitors such as fluvoxamine, and monitor glucose if using chronic >5 mg or if T2DM/prediabetes is already in the picture.
Most useful when sleep timing is the problem: delayed sleep phase, jet lag, shift work, or age-related low nighttime signal. The broader antioxidant, oncology-adjunct, MCI, and fertility uses have real papers behind them, but they are not the same evidence category as routine sleep-onset support.
Most common: next-day grogginess, vivid dreams, and 3-4 am wakeups when the dose is too high or too late. Chronic >5 mg use can lose effect within 4-8 weeks; high-dose protocols add glucose, mood, autoimmune, and product-quality concerns.
Excellent value: $5-15/month covers most OTC sleep use, while $15-40/month reconstitutable products mainly buy sub-milligram precision and better dose control. Cost is rarely the limiting factor; response quality, timing discipline, and product accuracy are.
Clinical effect on sleep onset is real but modest (~10-15 minute latency reduction across RCTs). Community confidence is highest for jet lag and circadian misalignment; high-dose longevity use is more bullish-but-bounded, with mechanism and adjunctive evidence ahead of long-term outcome data.
Do not stack two melatonin-receptor agonists (melatonin + ramelteon, agomelatine, tasimelteon) — overlapping MT1/MT2 occupancy gives no additional sleep benefit and amplifies grogginess and glucose impairment.
Intro
Melatonin is the body's circadian-timing hormone. The pineal gland secretes it in response to darkness, building from tryptophan through serotonin via the rate-limiting enzyme arylalkylamine N-acetyltransferase (AANAT), which is blocked by light reaching the retina. Endogenous peak plasma concentrations in young adults reach 80-120 pg/mL at night and fall below 10 pg/mL during the day. By age 70, pineal output drops roughly 80% from its young-adult peak — a decline that drives interest in melatonin as replacement therapy rather than just as a sleep drug.
It was discovered in 1958 by dermatologist Aaron Lerner, isolated from bovine pineal glands while looking for a skin-lightening factor. For three decades it sat as a niche endocrine curiosity. Two findings changed that: first, the discovery that melatonin is synthesized not just by the pineal but by nearly every tissue (gut, retina, lymphocytes, bone marrow, and inside individual mitochondria) — making it a paracrine and intracellular regulator, not just a circulating signal. Second, the discovery that it directly scavenges reactive oxygen species through electron donation from its indole ring, with its own oxidation products also acting as radical scavengers in a cascade. This systemic-antioxidant framing is the biological basis for the supraphysiologic-dose camp.
Mainstream sleep medicine uses melatonin at 0.3-5 mg for delayed sleep phase disorder, shift work disorder, jet lag, and pediatric autism spectrum sleep problems. The EU and several other jurisdictions approved prolonged-release formulations (Circadin 2 mg, Slenyto pediatric) for these indications. The US treats melatonin as an unregulated supplement, which explains both its widespread mass-market availability and the J Clin Sleep Med finding that 70% of tested OTC products were off-label by up to 10%, with some samples containing serotonin contamination.
The practical debate is dose tier. The low-dose camp argues that hormones work at small concentrations, a 0.3 mg dose approximates physiological nighttime signaling, and 5-10 mg pills overshoot physiology by 10-100x without proportional sleep benefit. The high-dose camp argues that antioxidant and mitochondrial effects only emerge at supraphysiologic exposure — commonly 30-300 mg nightly. Both camps converge on one useful point: the standard pharmacy 5-10 mg middle dose is often wrong-on-both-ends, too high to mimic physiology and too low to clearly test the antioxidant thesis. Most pragmatic users still take 1-5 mg as a sleep aid despite that debate.
Observed Effects
Primary intended effects. Sleep onset latency reduction averages 7-15 minutes in adult RCTs (Cruz-Sanabria 2024 dose-response meta-analysis, Posadzki 2017 umbrella review SMD 0.33, 95% CI 0.10-0.56).
Effect is most pronounced in phase-shift conditions: delayed sleep phase, jet lag, shift work disorder. A 60-day blinded self-experiment (n=1) found 0.3 mg cut latency from 35 to 25 minutes (p~0.001) with no added benefit from a higher dose. An 80.9% favoring-melatonin signal across 215 meta-analytic comparisons (Scoping Review 2025, 57 systematic reviews) confirms the effect is real and consistent, even though absolute size is modest. Total sleep time gain averages 8-20 minutes; sleep efficiency improvement is small with low certainty.
Cardiometabolic effects (63-RCT dose-response meta-analysis, 2025). Systolic blood pressure -2.34 mmHg (95% CI -4.13, -0.55). Fasting blood glucose -11.63 mg/dL (95% CI -19.16, -4.10). LDL cholesterol -6.28 mg/dL. Total cholesterol -6.97 mg/dL. C-reactive protein -0.59 mg/L. TNF-alpha -1.61 pg/mL. IL-6 -6.43 pg/mL. Malondialdehyde -1.54 μmol/L. The cardiometabolic and inflammation reductions appear with chronic dosing across heterogeneous trial designs.
Tension: glucose handling acute vs chronic. A controlled study in 21 healthy adults found a single 5 mg dose taken before a glucose tolerance test raised glucose AUC by approximately 186% in the morning and 54% in the evening — morning doses suppressed insulin release, evening doses suppressed insulin sensitivity. The chronic meta-analytic FBG reduction and the acute GTT impairment are not contradictions: they reflect different timing relative to feeding. Practical implication is timing-based — do not eat after dosing.
Perioperative. Posadzki umbrella review: surgical patients given melatonin 3-6 mg pre-op had first-analgesic-requirement time SMD 5.81 (95% CI 2.57-9.05) and reduced postoperative delirium incidence in elderly populations. Pre-op anxiolysis is comparable to midazolam at these doses.
Female reproductive and fertility context. Assisted reproductive technology trials showed melatonin 3-6 mg increased top-quality embryo yield SMD 0.53 (95% CI 0.27-0.79), attributed to follicular-fluid antioxidant effect.
Cognitive function in MCI. Alzheimer's Research & Therapy 2025 multi-dimensional meta-analysis showed modest but consistent improvement across MMSE, ADAS-Cog, and clinical dementia rating measures in adults with mild cognitive impairment.
Cardioprotection. Báez-Ferrer/Reiter 2021 meta-analysis (Frontiers Cardiovascular Medicine) showed reduced myocardial ischemia-reperfusion injury markers in human RCTs. Mechanism: mitochondrial protection during reperfusion oxidative burst.
Oncology adjunct. Multiple oncology-adjunct papers evaluate 20 mg/day melatonin during chemotherapy with reduced pooled 1-year mortality risk-ratio. Off-label, not standard of care, but consistent enough across trials that the high-dose community treats it as the strongest non-sleep use case.
Community reports (long-COVID/ME/CFS). One self-report case reported 80-90% recovery from moderate-severe ME/CFS using 5 mg three times daily (15 mg total split AM/PM/HS) over three months. n=1, not blinded, but specific and reproducible enough to have spawned a small protocol following.
Subjective vs objective gap. Users routinely report being 'much better rested' when their objective sleep-onset latency dropped only 10 minutes. This may reflect actual sleep-architecture changes (REM facilitation, sleep-spindle enhancement) or placebo. The effect is real for users either way.
Field Reports
What works. Lower doses than the bottle says. Across blinded n=1 testing, long-form user logs, and chronobiotic protocols, the consistent pattern is that 0.3-1 mg is often enough for sleep onset in responders. Higher doses add side effects faster than they add benefit.
Timing earlier. A recurring 3-4 am wake-up pattern often improves when the user reduces dose and moves timing earlier, sometimes 4-6 hours before target bedtime rather than right at bed. Melatonin is a phase-shift cue, not a knock-out drug.
Jet lag protocols. 0.3-0.5 mg before destination bedtime for 3-5 nights paired with morning sunlight on day 1 is the most consistently praised community use case.
Separated dosing in GH-peptide stacks. CJC-1295/Ipamorelin users commonly separate melatonin by 60-90 minutes from the peptide dose to avoid blunting the intended night pulse.
What doesn't work. Dose escalation as a tolerance solution. Pediatric and chronic-pain case logs show the same failure pattern: 2 mg works briefly, then 4-6 mg adds morning impairment without restoring effect. The fix is cycling off for 2-4 weeks, dropping to microdose, or switching strategies.
Treating melatonin as a sedative. Most disappointment traces back to expecting a Z-drug-like knockout. Melatonin signals darkness and sleep timing; it does not reliably sedate a wired user through stress, stimulants, pain, alcohol, or bad light exposure.
Taking with food. The glucose data is unambiguous enough for practice: 5 mg before a glucose challenge raised AUC 186% in the morning. Late-night snacking during elevated-melatonin windows is the documented worst case.
Common mistakes. Buying random OTC brands. Product assays found 70% of tested products off-label and some contaminated with serotonin. Pharmaceutical-grade, independently assayed, or reconstitutable precision products make more sense than bargain gummies for chronic use.
Ignoring CYP1A2 interactions. Fluvoxamine raises melatonin AUC 17-19x, and other strong CYP1A2 inhibitors can push a normal dose into high-dose exposure territory.
Using high-dose protocols without metabolic labs. Protocols in the 30-300 mg range should not be treated like ordinary sleep supplementation. Users in that lane should track fasting glucose, A1c, lipids, and inflammation markers at baseline and roughly 3-month cadence.
Honest failure modes. A blinded 28-day n=1 trial found no detectable sleep-extension benefit at 0.3 or 3 mg in either immediate- or extended-release form when baseline sleep was already optimized. Some people simply do not respond.
The autoimmune flare case is the most worrying real-world report: F/57, 5 mg daily, severe progressive autoimmune symptoms over weeks, and eight months for symptoms to resolve after discontinuation. The mechanism is biologically plausible because melatonin modulates T-cell and cytokine activity.
Extreme-dose user logs repeatedly surface vivid/lucid dreams, short depressive episodes, and fatigue around the 30 mg+ threshold. That does not make low-dose melatonin dangerous; it means the high-dose lane deserves different monitoring and expectations.
Community Consensus
The melatonin community is bimodal and the split is intentional. The sleep-medicine / chronobiotic position converges on 0.3-1 mg or no routine melatonin at all.
The argument is straightforward: hormones work at small concentrations, endogenous nighttime plasma peaks around 80-120 pg/mL, a 0.3 mg dose can approximate that signal, and 5-10 mg pills often overshoot physiology by 10-100x without proportional sleep benefit.
The high-dose longevity camp argues from a different evidence base. Mitochondrial accumulation, direct radical scavenging, SIRT1/SIRT3 activation, oncology-adjunct data around 20 mg/day, and age-related pineal-output decline all support the idea that supraphysiologic doses may be doing something separate from sleep timing. This camp is bullish but bounded: the mechanism is plausible and the adjunctive literature is real, but the 30-300 mg self-experimentation lane does not have the same long-term safety or outcome footing as low-dose circadian use.
The middle ground — the 5-10 mg dose that makes up much of the pharmacy and gummy market — is the least intellectually defended lane. It is too high for physiological replacement and often too low to clearly test the antioxidant thesis. Pragmatic mainstream users still take 1-5 mg as a sleep aid, but the best community guidance usually pulls people downward for timing or upward only if they knowingly enter the experimental antioxidant lane.
Performance-drug users treat melatonin as sleep infrastructure inside heavier stacks. Trenbolone, contest prep, stimulants, and high-cortisol phases can disrupt sleep hard enough that 10 mg IR plus 5-10 mg ER appears in community protocols alongside glycine, ZMA, GABA, and serotonin-precursor support. That is not a general sleep-health protocol; it is a time-limited rescue pattern for chemically induced sleep disruption.
Adoption is wide but shallow. Less than 30% of OTC starters still use melatonin at 6 months in the available community synthesis. Discontinuation is usually driven by tolerance at >5 mg, vivid dreams, morning grogginess, mid-night waking, or realizing timing matters more than dose.
Risks & Monitoring
Dose-response spectrum. Melatonin's adverse-effect profile is genuinely dose- and timing-graded, not a frequency-bucket list.
The same compound is well-tolerated at 0.3-1 mg and produces consistent next-day impairment at 5+ mg, particularly in older adults. The mechanism that creates this gradient is straightforward: melatonin plasma half-life is 30-60 minutes for immediate-release, but elimination relies on hepatic CYP1A2 metabolism, which slows progressively with age. A 5 mg dose keeps plasma 10x above physiological peak six hours after ingestion (Garaulet 2020); in older adults the residual extends well into morning.
Morning grogginess and 'sleep hangover'. Most common at 3-10 mg. Community case logs show this at ordinary prescription and OTC doses. Resolves with dose reduction, not dose escalation. Older adults experience this disproportionately due to age-slowed CYP1A2 and renal clearance.
Vivid and disturbing dreams. Dose-dependent. Rare at <1 mg, common at 5+ mg, prominent at 30+ mg. Reported across lucid-dream, extreme-dose, and pediatric sleep contexts. Some users find this desirable; most find it disruptive.
Glucose tolerance impairment. Single 5 mg before glucose challenge raised AUC 186% morning / 54% evening in n=21 healthy adults. In type 2 diabetics, 10 mg nightly for 3 months reduced insulin sensitivity ~12% measured by hyperinsulinemic-euglycemic clamp (n=17, gold-standard methodology). Practical: do not eat after dosing; reduce or stop in metabolic-disease populations.
Tolerance and rebound insomnia. Receptor desensitization via GRK/arrestin-mediated MT1/MT2 internalization occurs within hours to days of sustained high exposure (Liu 2016). Community synthesis: 60-70% of long-term users develop tolerance within 4-8 weeks. Endogenous production does NOT shut down (no negative feedback loop established) but receptor sensitivity drops. Discontinuation typically produces 3-10 days of rebound insomnia.
Mood effects at high doses. Specific to 30 mg nightly — independent corpus references and extreme-dose logs document depression and fatigue at this threshold. This is a discrete dose-toxicity zone, not a continuous gradient. Below 10 mg, mood effects are uncommon.
Autoimmune flare risk. One detailed case report (F/57/130 kg, 5 mg daily for pain-related insomnia) described severe autoimmune flare with fatigue, cognitive fog, IBS, and pain progression over several weeks; symptoms took eight months to resolve after discontinuation. Suggests immune-activating effect in autoimmune-active populations. Caution is warranted for users with active autoimmune disease.
Memory and learning context. In mouse hippocampal slices, melatonin at 100 nM reduced long-term potentiation by ~50% through MT2-mediated cAMP/PKA pathway inhibition. Raises a theoretical concern about high-dose chronic use and memory consolidation. Human evidence sparse.
Reproductive hormone fluctuation. Short-term reductions in FSH, LH, and estradiol have been documented in healthy individuals (Limbachiya IJPS review) but no persistent HPG suppression has been demonstrated. One corpus reference notes high-dose melatonin inhibits morning testosterone synthesis, likely due to residual sustained-release extending into the AM peak window.
Quality control hazard. J Clin Sleep Med analysis: 70% of 31 OTC products tested were up to 10% off-label; some samples contained serotonin contamination. Serotonin contamination is a meaningful safety issue at sustained use in serotonin-sensitive users.
Pediatric considerations. Tolerance pattern emerges in pediatric prescription use at typical doses: 2 mg can work initially, then lose efficacy after ~2 months, with escalation to 4-6 mg failing to solve the problem. Reproductive-hormone timing-of-puberty concerns flagged but not clearly demonstrated.
Drug interactions. Fluvoxamine (CYP1A2 inhibitor) raises melatonin AUC 17-19x — co-use produces hypothermia, profound sedation. Other strong CYP1A2 inhibitors (fluoroquinolones, cimetidine) similar magnitude. Beta-blockers (propranolol) suppress endogenous melatonin via beta-adrenergic regulation of pineal AANAT — patients on these drugs may develop iatrogenic deficiency.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Not needed for ordinary 0.3-3 mg sleep use. Use baseline labs before chronic >5 mg dosing, supraphysiologic protocols, or any use in T2DM/prediabetes because 10 mg nightly for 3 months reduced insulin sensitivity ~12% in a T2DM clamp study.
Re-check at 3 months for chronic >5 mg dosing, supraphysiologic protocols, or T2DM/prediabetes. Discontinue or reduce dose if fasting glucose or HbA1c drifts upward.
For users on supraphysiologic doses (>30 mg). Tracks hepatic enzymes and kidney function annually given high-dose chronic exposure has limited safety surveillance.
Meta-analytic data shows -6.28 mg/dL LDL and -6.97 mg/dL TC with chronic supplementation. Useful as a measurable outcome rather than a safety check for users pursuing cardiometabolic benefits.
For users explicitly pursuing the anti-inflammatory use case at supraphysiologic doses. Track at 3-6 months — meta-analytic effect sizes -0.59 mg/L CRP, -1.61 pg/mL TNF-alpha, -6.43 pg/mL IL-6.
Only for users on chronic high-dose sustained-release where residual extends into morning hours; high-dose melatonin reportedly inhibits morning testosterone synthesis. Switch to IR-only if AM total T trends down.
Avoid With
Do not combine Melatonin with the following. Sorted highest-severity first.
Why:Fluvoxamine inhibits CYP1A2 and raises oral melatonin AUC 17-19x — turns a 3 mg dose into an effective 50-60 mg dose. Produces severe sedation, hypothermia, and prolonged morning impairment.
What to do:If on fluvoxamine, reduce melatonin to 0.1-0.3 mg or avoid entirely. Watch for fluoroquinolones (ciprofloxacin), cimetidine, and other CYP1A2 inhibitors — similar interaction magnitude.
Why:MT1 and MT2 receptors saturate at standard doses; stacking adds no efficacy and compounds desensitization, grogginess, and glucose-handling impairment.
What to do:If transitioning between melatonin-receptor drugs, do not overlap. Pick one. Agomelatine combines MT1/MT2 agonism with 5-HT2C antagonism for depression, but using it alongside oral melatonin defeats its receptor-selectivity premise.
Why:Serotonin contamination has been documented in some OTC melatonin samples (J Clin Sleep Med analysis). Combined with serotonergic drugs this creates a small but real serotonin syndrome risk. Mechanism of melatonin itself does not include serotonin receptor agonism, so this is a product-quality, not pharmacology, issue.
What to do:Use a pharmaceutical-grade or peptide-grade reconstitutable product if on SSRIs. Avoid bulk OTC unless brand has independent assay verification.
Why:Anecdotal INR variability reported with melatonin co-use; mechanism unclear but may involve hepatic enzyme modulation.
What to do:If on warfarin, check INR more frequently when starting or stopping melatonin. Effect inconsistent but worth tracking.
Why:Melatonin has immune-activating effects in autoimmune populations. One detailed case report (5 mg daily, F/57) described severe autoimmune flare requiring 8 months for symptoms to resolve after discontinuation.
What to do:Avoid in active autoimmune disease unless under physician supervision. The immune effect may partially counter immunosuppressant therapy.
Why:Elevated plasma melatonin during glucose challenge raises AUC 186% morning / 54% evening (n=21 healthy adults). MTNR1B variant carriers more susceptible.
What to do:Stop eating 2+ hours before dosing. No midnight snacks if you wake during sustained-release coverage.
Why:Beta-blockers suppress endogenous pineal melatonin via beta-adrenergic regulation of AANAT. Combined with exogenous melatonin this is not dangerous, but it changes the rationale — supplementation here is replacement, not augmentation.
What to do:Patients on chronic propranolol can develop iatrogenic melatonin deficiency. Time exogenous dose to physiological nighttime peak (around 11 pm). The same beta-blocker effect can be exploited in reverse: morning melatonin can phase-flip circadian rhythm in beta-blocked patients.
Why:Residual melatonin into morning suppresses morning testosterone synthesis (corpus reference). For users tracking AM total T, this can blunt the morning peak.
What to do:If using long-half-life formulations, time dose earlier so plasma falls before AM cortisol/T peak. IR formulations don't have this issue.
Protocols By Goal
Sleep onset (delayed sleep phase, occasional insomnia). 0.3-3 mg, 30-90 minutes before bed. Lower end if any next-day grogginess. Track effective onset latency over 5-7 nights before escalating.
Jet lag. 0.3-0.5 mg, 30 minutes before target local bedtime for 3-5 nights at destination. Morning sunlight day 1. Eastward shifts are harder than westward; consider extending protocol to 7 nights for >6 timezone shifts.
Shift work disorder. 0.5-3 mg before main sleep period (which may be daytime). Blackout shades essential — exogenous melatonin works against bright light suppression of endogenous signaling.
Longevity / anti-aging. Two camps with different protocols. Low-dose camp: 0.3-1 mg nightly framed as physiological replacement for age-related decline. High-dose camp: titrate to 30-200 mg nightly framed as supraphysiologic antioxidant and mitochondrial accumulation. Both camps avoid the 5-10 mg middle ground. Choose based on tolerance for next-day effects and existing comfort with biohacker-tier doses.
Cancer adjunct. 20 mg nightly with chemotherapy, single evening dose. Requires physician coordination especially around chemotherapy timing — melatonin's effect on hepatic enzymes can affect chemo drug metabolism.
Cardiometabolic risk-marker improvement. 3-10 mg nightly chronic. Track FBG, A1c, LDL, hsCRP, IL-6 at baseline and 3-6 months. Do not eat after dosing — acute pre-meal melatonin worsens glucose handling.
Fertility / IVF. 3-6 mg nightly during ART cycle. Evidence base specific to follicular-fluid antioxidant effect on embryo quality.
Perioperative anxiolysis. 3-6 mg pre-op, single dose. Reduces first-analgesic-requirement time and incidence of post-op delirium in elderly.
Adjunctive in mild cognitive impairment. 2-10 mg nightly. Evidence base is modest improvement in MMSE and ADAS-Cog over 3-6 months. Sleep co-benefit common.
On-cycle AAS sleep rescue. 10 mg IR + 5-10 mg ER + sleep stack (5-HTP, glycine, ZMA, GABA). Time-limited to cycle duration. Not for chronic year-round use.
Older adults (age 60+) for sleep. 0.1-0.5 mg only, taken 1-3 hours before bed (earlier than younger adults). Age-related CYP1A2 slowing extends residual; dose reduction prevents morning grogginess. EU-approved prolonged-release Circadin 2 mg is the established prescription option in this population.
Pediatric ASD sleep (prescription context only). 2 mg starting, titrate to 4-6 mg as needed. Slenyto (EU-approved prolonged-release pediatric) is the standard-of-care product. Note community-documented tolerance pattern within 2 months.
Dosing Details
Standard sleep dose. 0.3-3 mg taken 30-90 minutes before desired sleep onset. Optimal sleep-onset benefit plateaus around 3-5 mg; higher doses add next-day grogginess without proportional onset improvement (Cruz-Sanabria 2024 dose-response meta-analysis). Take in darkness or under dim light to avoid undoing the signal with bright exposure. Do not eat after dosing — elevated melatonin during glucose challenge raises AUC 186% in morning and 54% in evening.
Microdose / physiological replacement. 0.3-0.5 mg, taken 60-90 minutes before bed. Replicates endogenous nighttime peak (80-120 pg/mL) without the 10-100x supraphysiologic exposure of standard OTC pills. This is the cleanest long-term nightly lane when the goal is circadian signaling rather than sedation.
Form choice. Immediate-release (IR) for sleep-onset problems — Cmax in 30-60 minutes, plasma half-life 30-60 minutes, no sustained coverage. Prolonged-release / sustained-release (SR) for sleep-maintenance problems — coverage extends 6-8 hours. EU-approved prolonged-release Circadin (2 mg) targets sleep maintenance in adults over 55. Combined IR + SR is the community workaround for both-end problems: 1-3 mg IR for onset + 1-3 mg SR for maintenance. Higher-dose AAS-cycle protocols use 10 mg IR + 5-10 mg ER for full-night coverage during compound-induced sleep disruption.
Reconstituted peptide-grade form. A 10 mg lyophilized vial reconstituted with 1 mL bacteriostatic water yields a 10 mg/mL concentration: 0.3 mg = 3 units on an insulin syringe, 0.5 mg = 5 units, 1 mg = 10 units, 3 mg = 30 units, 5 mg = 50 units. Reconstituted product is administered subcutaneously, intranasally, or sublingually depending on the product. The advantage is sub-milligram precision that pill form cannot match and bypass of CYP1A2 first-pass metabolism for more predictable plasma levels. Storage: refrigerate post-reconstitution, use within 28 days.
Jet lag / phase-shift protocol. 0.3-0.5 mg taken 30 minutes before the target local bedtime, repeated for 3-5 nights post-arrival. Pair with morning sunlight on day 1 for fastest re-entrainment. Eastward travel (advance) typically harder than westward (delay). The same logic can be flipped in special cases, but ordinary users should treat morning melatonin as an advanced circadian intervention.
Anti-aging / longevity protocol (high-dose camp). Community titration usually starts around 5-30 mg in the evening for 2-4 weeks, then escalates 5-10 mg every 1-2 weeks if morning grogginess stays tolerable. Steady-state targets vary widely, often 50-200 mg, with some extreme logs above that. This is an experimental antioxidant/mitochondrial lane, not ordinary sleep supplementation, and it loses formal long-term safety surveillance.
Stress / acute oxidative event protocol. 20-100 mg nightly, time-limited (days to weeks), used pre/post radiation, during acute viral illness, or high-cortisol life events. Return to maintenance dose after.
Long-COVID / ME/CFS protocol. One forum-documented case used 5 mg three times daily (15 mg total split AM/PM/HS) for 3 months. Initial 3 days of daytime drowsiness; counter with coffee. Not a clinically validated protocol; n=1 case report with reproduced community use.
On-cycle AAS sleep protocol. 10 mg IR at bedtime + 5-10 mg ER for maintenance, stacked with 5-HTP 200 mg, glycine 3 g, ZMA, GABA. Total melatonin load 15-20 mg per night. Used to counter trenbolone, contest-prep, and high-cortisol AAS-induced sleep disruption.
Tolerance management. Chronic >5 mg use loses efficacy by week 4-8. Cycling off for 2-4 weeks restores receptor sensitivity. Dose escalation does NOT resolve tolerance — community failure pattern. If tolerance develops, drop to microdose or stop entirely, not push higher.
Timing-not-dose troubleshooting. When 5 mg pre-bed produces 3-4 am wake-up, the fix is reducing dose to 0.3-1 mg AND moving timing earlier (4-6 hours before target bedtime rather than at bedtime). Do not treat mid-night waking as a reason to escalate dose.
Stacks & Alternatives
Standard pre-bed sleep co-stack. Magnesium relaxes neuromuscular tone and supports GABA-A binding. Common 200-400 mg with melatonin at bedtime. L-threonate form preferred when cognitive-protective effect is also targeted.
Pre-bed glycine helps core temperature drop required for sleep onset. Community-routine co-stack with melatonin, appearing across TRT and AAS sleep protocols. Cheap and well-tolerated.
Adds GABAergic tone for users where melatonin alone doesn't quiet pre-sleep arousal. Caution: high-dose GABA stacks (3 g+) can phase-delay circadian rhythm and reduce morning GABAergic signaling.
Serotonin precursor; some users prefer this upstream of endogenous melatonin synthesis. Watch for serotonin syndrome risk with concurrent SSRIs or MAOIs.
Standard pre-bed micronutrient stack. Zinc supports endogenous testosterone, magnesium supports relaxation. Routine pairing with melatonin in performance contexts.
GH-axis peptides are often co-stacked with melatonin at bedtime to support sleep-linked GH pulsatility. Community guidance separates doses by 60-90 minutes because overlapping doses may blunt the intended night pulse.
Oral GH secretagogue. Stacks with bedtime melatonin for sleep-onset and GH-pulse co-optimization. Watch combined morning grogginess — both have residual effect.
Anxiolytic without sedation. Reduces pre-sleep rumination. Common in commercial sleep-blend products containing melatonin 200 mcg/mL with GABA, glycine, L-theanine, taurine.
Bioflavonoid GABA-A positive modulator used as a melatonin alternative; also stacks with low-dose melatonin without receptor overlap.
Hepatobiliary and glutathione support paired with melatonin in longevity-camp anti-aging stacks. No mechanistic conflict; addresses different oxidative defense pathways.
Alternatives
Stack Cost
Melatonin sits cleanly in most stacks at sleep doses but consumes monitoring and timing capacity once dosing crosses into supraphysiologic territory (>10 mg) or in metabolic-disease populations.
At 0.3-3 mg sleep doses, no routine bloodwork required. At chronic >5 mg, supraphysiologic dosing, or T2DM/prediabetes, FBG and A1c at 3-month cadence become advisable. Supraphysiologic >30 mg protocols can justify CMP and inflammation markers as outcome/safety tracking.
$5-40 per month across all use cases. Among the least expensive sleep interventions on the market.
Fluvoxamine (17-19x AUC), other CYP1A2 inhibitors, beta-blockers, SSRIs/MAOIs with contaminated product, warfarin INR variability, immunosuppressants. Several real interactions but rarely surprises and all manageable with awareness.
Vivid dreams, morning grogginess, and 30 mg depression/fatigue threshold are dose-dependent and reversible. Not a chronic CNS burden at typical doses.
Acute pre-meal melatonin worsens glucose AUC dramatically (186% morning, 54% evening). Chronic >5 mg reduces insulin sensitivity ~12% in T2DM by clamp. Real metabolic capacity cost; needs respecting in metabolic-disease users.
- ·Do not stack with other melatonin receptor agonists (ramelteon, agomelatine, tasimelteon) — receptor saturation makes the second drug redundant.
- ·Do not stack with fluvoxamine without reducing dose 10-20x — interaction is severe.
- ·Do not eat after dosing — pre-meal melatonin worsens glucose handling 54-186%.
- ·For users on chronic supraphysiologic doses (>30 mg), commit to baseline + 3-month metabolic bloodwork.
- ·Cycle off after 4-8 weeks at chronic >5 mg dosing — tolerance develops via MT1/MT2 receptor desensitization.
- ·Blackout sleeping environment to avoid undoing the signal
- ·Pre-bed timing discipline (no eating, no bright light)
- ·OTC quality verification (USP-grade, third-party assay, or peptide-grade reconstitution)
- ·Baseline + periodic FBG/A1c only if running chronic >5 mg, supraphysiologic dosing, or in metabolic-disease users
- ·Cycling structure if running chronic high dose (4-8 weeks on, 2-4 weeks off)
Hard to acutely hurt yourself even at substantial overdose at OTC doses. Side effects are uncomfortable but reversible. Forgiving for first-time users learning what sleep-supplement response feels like.
- ·Active autoimmune disease (immune-flare risk documented)
- ·Type 2 diabetes considering chronic >5 mg dosing
- ·Currently on fluvoxamine or other strong CYP1A2 inhibitor
- ·Pregnant or actively trying to conceive
Discontinuation at low doses typically uneventful. Chronic >5 mg use produces 3-10 days of rebound insomnia upon stopping as receptor sensitivity returns. Glucose handling and inflammation effects reverse within weeks of discontinuation.
- ·3-10 days rebound insomnia after chronic >5 mg use
- ·Return of pre-supplementation sleep pattern
- ·Loss of any cardiometabolic marker improvements over weeks
Do not escalate. Cycle off 2-4 weeks to restore receptor density, then resume at lower dose or rotate to a different sleep tool.
Reduce dose 50% or take 1-3 hours earlier. Older adults disproportionately affected — drop to 0.1-0.5 mg.
Reduce dose AND move timing earlier (4-6 hours before bed, not at bed). Do not escalate dose — common failure pattern.
Discontinue or reduce to <3 mg. Re-check metabolic panel at 1-3 months post-reduction.
Documented immune-flare case (F/57) with severe progression over weeks and 8-month resolution after discontinuation. Mechanism plausible — melatonin has T-cell and cytokine modulating effects.
Chronic 10 mg melatonin reduced insulin sensitivity ~12% by clamp methodology in T2DM patients (n=17, 3 months). Pre-meal acute dosing worsens glucose AUC 54-186%.
AUC increases 17-19x — turns a 3 mg dose into an effective 50-60 mg dose with severe sedation and hypothermia.
Crosses placenta freely; high-dose disrupts fetal circadian development in animal models. Default contraindication.
Practical Setup
Quality control. OTC melatonin in the US is an unregulated supplement category — J Clin Sleep Med assayed 31 products and found 70% had content off-label, with some samples containing serotonin contamination.
Practical mitigations are quality-control oriented: pharmaceutical-grade or USP-verified products, independent third-party assay verification, and dose forms that can measure sub-milligram amounts reliably.
Precision-dose forms. Community users sometimes discuss reconstitutable or non-tablet formats for sub-milligram dosing precision. The useful public-facing point is measurement accuracy, sterility expectations for any non-oral route, cold storage after reconstitution, and avoiding improvised dose math. This article should not function as a reconstitution guide.
Regulatory context. Product status differs by country: melatonin is sold as an OTC supplement in the US, while many EU/UK/Commonwealth markets treat it as prescription-only. The article frames that as legal variability and quality-control context, not as cross-border access guidance.
Storage and stability. Tablets at room temperature; refrigerate after reconstitution. Melatonin is light-sensitive — store in opaque containers or original blister packaging. Sustained-release formulations particularly sensitive to moisture; close tightly.
Signs to adjust protocol. Morning grogginess persisting more than 2 hours after waking → reduce dose 50% or move timing earlier. Vivid/disturbing dreams interfering with sleep → reduce dose. 3-4 am wake-up not resolving with the same dose → reduce dose AND move timing earlier (do not escalate). Fasting glucose trending up >5 mg/dL or A1c climbing >0.3 pp → consider discontinuation in metabolic-disease users. Mood flattening or fatigue not present pre-supplementation → dose likely above 10 mg, reduce.
Forms and formulations. Immediate-release tablets/capsules — 0.3 mg microdose products up through 10 mg consumer pills and 20+ mg specialty products. Sublingual and dissolvable forms — faster onset, useful for delayed-sleep-phase users with already-narrow window. Prolonged-release (Circadin, Slenyto, several US OTC versions) — releases over 6-8 hours for maintenance. Liposomal — claimed enhanced bioavailability; data thin. Reconstitutable peptide vials — sub-milligram precision, route flexibility. Combination sleep blends with GABA, glycine, theanine, taurine, or magnesium are common, but blend labels make clean dose-response interpretation harder.
Timing rules. Take 30-90 minutes before desired sleep onset for immediate-release. Take 1-3 hours before bed for prolonged-release. Older adults: take 1-3 hours earlier than younger adults due to slower CYP1A2 clearance. Do not eat after dosing — Garaulet glucose data established a clear pre-meal danger window. If you wake in the middle of the night, do not take additional melatonin; you risk pushing residual into the morning.
Drug interactions to surface. Fluvoxamine and other CYP1A2 inhibitors raise plasma AUC dramatically. Beta-blockers blunt endogenous melatonin so supplementation acts as replacement rather than augmentation. SSRIs and MAOIs carry small theoretical serotonin syndrome risk via contaminated OTC product. Warfarin INR variability reported. Immunosuppressants and active autoimmune disease — caution flag, possible immune-flare risk.
Tracking your response. Subjective sleep-quality questionnaire (PSQI) plus objective sleep tracker data over 2-4 week baseline before starting; same window during titration. Wear-only sleep trackers can be unreliable for total sleep time, so manual recording matters. Track morning glucose at 3-month milestones if using chronic >5 mg.
Cost expectations. OTC pills are usually inexpensive at standard doses; pharmacy prescription products vary by health system. Among the least cost-sensitive interventions in the sleep-and-longevity supplement space.
Mechanism Deep Dive
Receptor pharmacology. Melatonin binds two high-affinity G protein-coupled receptors: MT1 (gene MTNR1A) and MT2 (gene MTNR1B).
Both are expressed in the suprachiasmatic nucleus (SCN) — the central circadian pacemaker — plus retina, pancreatic beta-cells, vascular smooth muscle, immune cells, and adipocytes. MT1 mediates sleep promotion via SCN neuronal inhibition. MT2 mediates circadian phase shifts and sleep-spindle facilitation. Receptor pharmacology has yielded approved drugs (ramelteon dual MT1/MT2, tasimelteon MT2-biased, agomelatine MT1/MT2 plus 5-HT2C antagonist) targeting the same pathway.
Signaling cascades. Both MT1 and MT2 couple primarily to Gαi/o subunits, which inhibit adenylyl cyclase and reduce intracellular cAMP. Secondary coupling to Gαq activates phospholipase C and protein kinase C. Gβγ subunits modulate MAP kinase pathways and ion-channel gating. Receptors can homodimerize and heterodimerize with each other and with serotonin 5-HT2C, providing additional signaling diversity. Liu et al. 2016 and Hardeland 2009 are the foundational reviews.
Synthesis pathway. Tryptophan → 5-hydroxytryptophan (TPH) → serotonin (AADC) → N-acetylserotonin (AANAT) → melatonin (HIOMT). AANAT is the rate-limiting enzyme and is itself regulated by darkness through SCN → paraventricular nucleus → superior cervical ganglion → pineal beta-adrenergic input. Light reaching the retina via melanopsin-expressing intrinsically photosensitive retinal ganglion cells (ipRGCs) projects through the retinohypothalamic tract to the SCN. SCN GABAergic output to PVN suppresses pineal AANAT during daylight. This is why blue light at <100 lux can suppress nighttime melatonin onset by 50%+ and why beta-blockers (propranolol) reduce endogenous output.
Pharmacokinetics. Oral immediate-release: Cmax 30-60 minutes post-ingestion, plasma half-life 30-60 minutes. Bioavailability highly variable (3-76%) due to CYP1A2 polymorphisms and food interactions. First-pass hepatic CYP1A2 metabolism converts melatonin to 6-hydroxymelatonin, then to 6-sulfatoxymelatonin which is excreted in urine (the canonical biomarker for melatonin exposure). Prolonged-release formulations (Circadin EU 2 mg) maintain plasma elevation 6-8 hours through controlled release rather than altered metabolism.
Mitochondrial accumulation. Melatonin is lipophilic and crosses cell, mitochondrial, and nuclear membranes freely. Intramitochondrial concentrations exceed plasma, and mitochondria themselves synthesize melatonin locally (most peripheral cells produce their own melatonin for autocrine/paracrine action). Inside mitochondria it stabilizes the inner membrane, supports complex I/IV activity, and concentrates antioxidant defense at the major site of ROS production. This is the mechanistic basis for the high-dose anti-aging camp's framing.
Direct radical scavenging. Melatonin's indole ring donates electrons to neutralize hydroxyl, peroxyl, and peroxynitrite radicals. Each molecule can neutralize up to ~10 ROS in a cascade because its oxidation products (cyclic-3-hydroxymelatonin, AFMK, AMK) are themselves radical scavengers. This is receptor-independent and operates outside MT1/MT2 binding — a 'suicide' antioxidant mechanism that scales with concentration.
Enzyme upregulation (indirect antioxidant). At physiological levels melatonin upregulates glutathione peroxidase, superoxide dismutase, and catalase, and activates sirtuins SIRT1 and SIRT3. SIRT3 is mitochondrial — its activation connects sleep biology to mitochondrial resilience and inflammaging. This is a transcriptional effect, distinct from direct scavenging, and accumulates with chronic exposure.
Pancreatic islet effect. MT1 and MT2 are expressed on pancreatic beta-cells. Melatonin binding inhibits glucose-stimulated insulin secretion via Gαi-mediated cAMP suppression. Carriers of the MTNR1B rs10830963 G allele have exaggerated glucose response when eating during high-melatonin windows. This is the mechanistic basis for the Garaulet 186% AUC finding and for the practical rule against eating after dosing.
Sleep architecture effects beyond onset. Beyond shortening latency, melatonin facilitates sleep spindles (MT2-mediated), enhances REM sleep proportion, and modulates slow-wave activity. These are architectural — not sedative — effects, consistent with the chronobiotic framing.
Peripheral oscillator synchronization. Melatonin synchronizes peripheral oscillators in pancreas, liver, kidney, heart, lung, adipose tissue, and gut — not only the central SCN clock. Disrupted peripheral synchrony underlies metabolic dysfunction of chronic shift work. Melatonin timing affects glucose handling, lipid metabolism, and immune function through this pathway.
Nuclear and non-receptor binding. Beyond MT1/MT2, melatonin binds nuclear receptors RORα and RORβ, quinone reductase 2 (NQO2), calmodulin, and calreticulin. NQO2 binding may underlie some anti-cancer effects independent of receptor signaling. Calmodulin binding modulates calcium dynamics.
Tolerance / receptor desensitization. Chronic high-dose exposure produces GRK/arrestin-mediated MT1/MT2 internalization within hours to days. This explains community-reported tolerance to >5 mg dosing within 4-8 weeks. Endogenous synthesis is NOT shut off by exogenous melatonin (no canonical negative-feedback loop), but receptor sensitivity drops. Cycling off restores receptor density within 2-4 weeks.
Memory and learning context. In mouse hippocampal slices, 100 nM melatonin (achievable at supraphysiologic plasma) reduced long-term potentiation by ~50% through MT2-mediated cAMP/PKA inhibition. The same pathway that promotes sleep-spindle activity at lower exposure may blunt synaptic plasticity at chronic high exposure. Human in-vivo evidence sparse.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
Endogenous nighttime peak plasma concentrations in young adults reach 80-120 pg/mL at night and fall below 10 pg/mL during the day.
Aggregated from Tordjman 2017 pharmacology review covering multiple healthy-adult assay studies.
By age 70, pineal output drops roughly 80% from its young-adult peak.
Pineal output decline figure is community-cited and supported by multiple aging-melatonin reviews; specific magnitude is approximate.
Sleep onset latency reduction averages 7-15 minutes in adult RCTs.
Cruz-Sanabria 2024 J Pineal Research dose-response meta-analysis pooled effect.
Sleep onset latency SMD 0.33 (95% CI 0.10-0.56).
Posadzki 2017 umbrella review across 195 reviews.
60-day blinded n=1 self-experiment: 0.3 mg cut latency from 35 to 25 minutes (p~0.001).
Blinded design with hypothesize.io analysis; well-controlled but single-subject.
80.9% of melatonin-vs-comparator comparisons favored melatonin across 215 meta-analytic comparisons.
Scoping review of 57 systematic reviews containing 227 meta-analyses; 215 had vote-counting data.
Systolic blood pressure -2.34 mmHg (95% CI -4.13, -0.55).
63-RCT meta-analysis pooled effect size.
Fasting blood glucose -11.63 mg/dL (95% CI -19.16, -4.10).
63-RCT meta-analysis. Chronic dosing context; do not extrapolate to acute pre-meal exposure.
LDL cholesterol -6.28 mg/dL, total cholesterol -6.97 mg/dL.
Same 63-RCT meta-analysis.
C-reactive protein -0.59 mg/L; TNF-alpha -1.61 pg/mL; IL-6 -6.43 pg/mL; malondialdehyde -1.54 μmol/L.
Same 63-RCT meta-analysis. Anti-inflammatory and antioxidant marker effects.
Single 5 mg dose taken before glucose tolerance test raised glucose AUC by approximately 186% in the morning and 54% in the evening.
Garaulet study cited via Longevity Vault. Acute pre-meal context only — do NOT extrapolate to chronic dosing.
Surgical patients given melatonin pre-op had first-analgesic-requirement time SMD 5.81 (95% CI 2.57-9.05).
Posadzki umbrella review surgical sub-analysis.
ART trials showed melatonin 3-6 mg increased top-quality embryo yield SMD 0.53 (95% CI 0.27-0.79).
Wang 2022 umbrella review female reproductive sub-analysis.
Long-COVID/ME-CFS recovery case reported 80-90% recovery using 5 mg three times daily (15 mg total) over three months.
Single self-report case; not blinded, n=1, generalizability unclear.
Type 2 diabetics on 10 mg nightly for 3 months had insulin sensitivity reduced approximately 12% measured by hyperinsulinemic-euglycemic clamp.
Double-blinded crossover trial. Gold-standard clamp methodology. Specific to T2DM population; may not transfer directly to non-diabetic users.
5 mg keeps plasma 10x above physiological peak six hours after ingestion.
Garaulet 2020 cited via Longevity Vault. Age-related CYP1A2 slowing relevant context.
Fluvoxamine raises oral melatonin AUC 17-19x.
Drug-interaction study cited in Tordjman 2017 pharmacology review.
Mouse hippocampal slices: melatonin at 100 nM reduced long-term potentiation by approximately 50%.
Mouse in vitro. Human in vivo evidence sparse — do not extrapolate to clinical memory effects in adult users.
Oral immediate-release Cmax 30-60 minutes post-ingestion, plasma half-life 30-60 minutes.
Aggregated PK from Tordjman 2017.
Prolonged-release formulations (Circadin 2 mg) maintain plasma elevation 6-8 hours.
Circadin EMA registration data.
Bioavailability of oral melatonin is highly variable (3-76%).
Tordjman 2017 pharmacokinetic range due to CYP1A2 polymorphisms and food interactions.
70% of 31 OTC products had melatonin content up to 10% off-label, with some samples containing serotonin contamination.
J Clin Sleep Med product assay. Quality-control data, not clinical efficacy.
60-70% of long-term users develop tolerance within 4-8 weeks at chronic >5 mg dosing.
Cross-community synthesis. Self-report data, not clinical trial.
Less than 30% of OTC melatonin starters still take it at 6 months.
Cross-community synthesis. Adherence figure.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.